NCT00908141View on ClinicalTrials.gov

GM-CSF in Treating Patients With Relapsed Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

June 30, 2010

Study Completion Date

July 31, 2010

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

sargramostim

Given subcutaneously on varying schedule

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00908141 - GM-CSF in Treating Patients With Relapsed Prostate Cancer | Biotech Hunter | Biotech Hunter